Pearls on MRAs for T2D in CKD
Pearls on the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in CKD in T2D

Released: May 17, 2022

Expiration: May 16, 2023

Diana Isaacs
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP
Joshua J. Neumiller
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Activity

Progress
1
Course Completed

In this episode, Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP, and Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, discuss the use of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes, including:

  • Overview of chronic kidney disease
  • Guideline recommendations
  • Evidence for finerenone
  • Role of the pharmacist